Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group. Miyazaki Y, et al. Among authors: handa h. Int J Hematol. 2022 Aug;116(2):228-238. doi: 10.1007/s12185-022-03347-3. Epub 2022 May 4. Int J Hematol. 2022. PMID: 35508695 Clinical Trial.
Sacroiliitis as an initial manifestation of acute myelogenous leukemia.
Hoshino T, Matsushima T, Saitoh Y, Yamane A, Takizawa M, Irisawa H, Saitoh T, Handa H, Tsukamoto N, Karasawa M, Murakami H, Nojima Y. Hoshino T, et al. Among authors: handa h. Int J Hematol. 2006 Dec;84(5):421-4. doi: 10.1532/IJH97.06106. Int J Hematol. 2006. PMID: 17189223
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: handa h. Int J Hematol. 2010 Mar;91(2):276-83. doi: 10.1007/s12185-009-0480-5. Int J Hematol. 2010. PMID: 20054669 Clinical Trial.
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: handa h. Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6. Blood. 2011. PMID: 20693429 Free article. Clinical Trial.
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Miyawaki S, et al. Among authors: handa h. Blood. 2011 Feb 24;117(8):2366-72. doi: 10.1182/blood-2010-07-295279. Epub 2010 Dec 29. Blood. 2011. PMID: 21190996 Free article. Clinical Trial.
Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group.
Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y, Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R, Naoe T. Yoshida M, et al. Among authors: handa h. Int J Hematol. 2011 Jan;93(1):66-73. doi: 10.1007/s12185-010-0746-y. Epub 2011 Jan 7. Int J Hematol. 2011. PMID: 21213127
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T. Iriyama N, et al. Among authors: handa h. Ann Hematol. 2014 Jun;93(6):957-63. doi: 10.1007/s00277-014-2013-4. Epub 2014 Jan 19. Ann Hematol. 2014. PMID: 24441947
Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.
Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suenobu S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG). Hayakawa F, et al. Among authors: handa h. Blood Cancer J. 2014 Oct 17;4(10):e252. doi: 10.1038/bcj.2014.72. Blood Cancer J. 2014. PMID: 25325302 Free PMC article. Clinical Trial.
1,578 results